Novavax RSV Vaccine Shows Efficacy

In a Phase I clinical study, Novavax RSV vaccine candidate demonstrated high antibody response, a significant dose-response pattern, high rates of seroconversion at all doses.

Rockville-based biopharmaceutical company Novavax has received positive top-line results from a Phase I clinical study of its respiratory syncytial virus (RSV) fusion (F) recombinant nanoparticle vaccine candidate.

The blinded placebo-controlled dose-escalating Phase I trial enrolled 150 healthy adults, aged from 18 to 49 years old, who were allocated to six cohorts that included 4 dose levels of vaccine.

The study is intended to assess the safety and tolerability of aluminum phosphate-adjuvanted (adjuvant) and unadjuvanted formulations of its RSV vaccine candidate, while evaluating total and neutralising anti-RSV antibody responses and the impact of the adjuvant.

Novavax RSV vac